As a comparison drug and a cornerstone of oral antidiabetic treatment, we chose metformin; in order to test another approach for the treatment of the T2DM-associated neuropathy influencing gut-brain axis, we considered the enteric-soluble SCFAs such as PA due to its normalizing effect on fasting blood glucose, body weight and insulin tolerance [56]. This evidence concerns the gene INS and neuropathy.